Merck nears $6 bln deal for Terns Pharma, FT reports

Merck is nearing an all-cash acquisition of Terns Pharmaceuticals for roughly $6 billion, a premium to Terns' ~ $5.3 billion market capitalization. The deal is intended to bolster Merck's oncology pipeline ahead of potential Keytruda patent expiry as early as 2028 (Keytruda generates ~ $30 billion annually) and targets Terns' lead CML asset that could compete with Novartis' Scemblix. The move follows Merck's recent sizable deals (Verona ~$10B, Cidara ~$9.2B) as the company seeks to offset looming revenue losses from patent cliffs.

Analysis

This transaction is best read as a recalibration of how large-cap pharma will buy its way through an upcoming revenue cliff rather than build internally — that raises acquisition comps across small-cap oncology/rare-disease developers and compresses the pool of arbitrageable targets. Expect acquisition spreads for well-staged clinical assets to shrink to single-digit percentages within days of firm bids, while implied deal multiples for remaining public small biotechs re-rate higher on a go-forward basis.

Second-order competitive effects center on narrow-indication pricing and formulary dynamics: a new entrant in chronic myeloid leukaemia increases payer leverage and invites rebate/indication-limiting strategies from incumbents, which can cap realized peak sales to high-single-digit percentage penetration of current addressable populations; this turns headline market-share gains into multi-year, back-loaded revenue ramps. Manufacturing and scale-up timelines (6–24 months) create execution risk windows where value is sensitive to COGS and supply continuity — not just approval.

Key downside catalysts are deal failure, adverse trial/regulatory news on the acquired asset, or a payer push that forces materially lower net pricing; these can reverse sentiment inside weeks and remove takeover interest from similar names. Conversely, a confirmed close reduces target volatility but increases scrutiny on acquirer ROIC—if the market perceives overpayment, the buyer can trade down 8–15% over 3–12 months as investors price in dilution and integration costs.

Key Decisions for Investors

• Event-arb (target exposure): Buy the target equity up to a 6–12% downside stop relative to current price and size position to tolerate a 30–40% gap if deal breaks; expected upside is the spread to deal close within days–weeks, reward typically 5–15% vs binary risk — limit position size to 1–2% of portfolio.
• Pair trade (fundamental rotation): Long MRK equity (12–18 month horizon) / short NVS equity (12–18 month horizon) size 1:1. Rationale: MRK should re-rate on successful tuck-ins while NVS faces direct competitive pressure in CML. Target asymmetric payoff: seek 12–20% upside on long vs 15–25% downside protection on short; use 3–6% stop-loss on pair to control execution risk.
• Options hedge: Buy MRK 9–12 month calls (small position, 2–3% portfolio) to capture upside from further pipeline decorations and potential rerating; offset cost by selling near-term covered calls after a 6–10% pop post-close. Expect time decay but outsized payoff if additional strategic deals or positive clinical readouts occur.
• Selective small-cap exposure: Add modest long exposure to 2–3 pipeline-stage biotechs (e.g., CDTX-sized names) through LEAP calls with 12–24 month expiries to play continued M&A bid flow; keep position sizes small and diversify across indications to limit binary clinical risk.
• Risk control: Set portfolio-wide alert for any adverse payer/regulatory headlines or trial failures on similar CML assets; if one occurs, reduce biotech M&A exposure by 30–50% within 24–72 hours to avoid correlated mark-to-market drops.